Molecular Pharmacology Program
The Steven Larson Lab
My laboratory’s primary expertise is in molecular imaging, targeted radio diagnosis, and therapy using small molecules and monoclonal antibodies.
Currently, I am corresponding primary investigator of Memorial Sloan Ketterings’s In Vivo Cellular and Molecular Imaging Center (ICMIC) and coleader, with Ingo Mellinghoff and Charles Sawyers, of Research Project 4, studying molecular imaging correlates and biology of activation of the AR-axis in castrate-resistant prostate cancer. This project builds on extensive prior imaging collaborations with prostate cancer specialists Howard Scher, Michael Morris, and Peter Scardino and has led to the development of molecular imaging approaches to androgen receptor (AR) imaging as well as several novel radioantibodies that image downstream effectors of AR signaling.
Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med. 2014 Oct 29;6(260):260ra149. doi: 10.1126/scitranslmed.3009524. Epub 2014 Oct 29.
Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.PMID: 25143071
Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26.
Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK. Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight. 2016 May 5;1(6). pii: e87030.
Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807.
Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Sci Transl Med. 2016 Nov 30;8(367):367ra167. PMID:27903863
Steven M. Larson, MD
- Nuclear medicine physician Steven Larson focuses on molecular imaging in animals and humans using high-resolution diagnostic instruments, such as positron emission tomography, and single photon emission tomography.
- MD, University of Washington School of Medicine (Seattle)
- Molecular Pharmacology Program
- Department of Medicine
- Department of Radiology
- Center for Experimental Therapeutics
- Ludwig Center for Cancer Immunotherapy
- The Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center
- Center for Molecular Imaging & Nanotechnology
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Steven M. Larson discloses the following relationships and financial interests:
Samus Therapeutics LLC
Intellectual Property Rights
Ownership / Equity Interests
Y-mAbs Therapeutics, Inc.
Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.